Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR DysregulationTerence Hall(Arqule (United States)), Giovanni Abbadessa(Morristown Medical Center)PLoS ONESeptember 14, 201610.1371/journal.pone.0162594Cited by 84SaveCiteExport RISWatch citationsRelated PapersTivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study|The Lancet Oncology|2012|550